Lenalidomide selectively inhibits in vitro growth of the malignant clone in myelodysplastic syndrome (MDS) patients with 5q deletion.
Prif Awduron: | Jadersten, M, Pellagatti, A, Forsblom, A, Emanuelsson, E, Merup, M, Samuelsson, J, Wainscoat, J, Boultwood, J, Hellstorm-Lindberg, E |
---|---|
Fformat: | Conference item |
Cyhoeddwyd: |
2005
|
Eitemau Tebyg
-
Lenalidomide up-regulates SPARC and inhibits in vitro growth of the malignant clone in myelodysplastic syndrome patients with 5q deletion.
gan: Pellagatti, A, et al.
Cyhoeddwyd: (2006) -
Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
gan: Pellagatti, A, et al.
Cyhoeddwyd: (2007) -
Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.
gan: Jädersten, M, et al.
Cyhoeddwyd: (2009) -
Del(5q) Myelodysplastic Stem Cells Exhibit Their Clonal Advantage Via Increased Adhesion to the Microenvironment
gan: Scharenberg, C, et al.
Cyhoeddwyd: (2011) -
Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression
gan: Martin Jädersten, et al.
Cyhoeddwyd: (2009-12-01)